- Home
- KMPR vs SLNO Comparison
KMPR vs SLNO Comparison
Compare KMPR & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMPR
- SLNO
- Stock Information
- Founded
- KMPR 1990
- SLNO 1999
- Country
- KMPR United States
- SLNO United States
- Employees
- KMPR N/A
- SLNO N/A
- Industry
- KMPR Property-Casualty Insurers
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- KMPR Finance
- SLNO Health Care
- Exchange
- KMPR Nasdaq
- SLNO Nasdaq
- Market Cap
- KMPR 3.8B
- SLNO 3.2B
- IPO Year
- KMPR N/A
- SLNO 2014
- Fundamental
- Price
- KMPR $64.27
- SLNO $76.78
- Analyst Decision
- KMPR Strong Buy
- SLNO Strong Buy
- Analyst Count
- KMPR 4
- SLNO 9
- Target Price
- KMPR $78.25
- SLNO $103.33
- AVG Volume (30 Days)
- KMPR 536.7K
- SLNO 955.8K
- Earning Date
- KMPR 05-07-2025
- SLNO 05-07-2025
- Dividend Yield
- KMPR 2.00%
- SLNO N/A
- EPS Growth
- KMPR N/A
- SLNO N/A
- EPS
- KMPR 5.35
- SLNO N/A
- Revenue
- KMPR $4,687,400,000.00
- SLNO N/A
- Revenue This Year
- KMPR $9.33
- SLNO N/A
- Revenue Next Year
- KMPR $11.79
- SLNO N/A
- P/E Ratio
- KMPR $11.68
- SLNO N/A
- Revenue Growth
- KMPR N/A
- SLNO N/A
- 52 Week Low
- KMPR $53.57
- SLNO $36.93
- 52 Week High
- KMPR $73.01
- SLNO $80.91
- Technical
- Relative Strength Index (RSI)
- KMPR 62.63
- SLNO 65.28
- Support Level
- KMPR $60.23
- SLNO $72.23
- Resistance Level
- KMPR $60.06
- SLNO $80.99
- Average True Range (ATR)
- KMPR 1.71
- SLNO 3.06
- MACD
- KMPR 0.87
- SLNO -0.37
- Stochastic Oscillator
- KMPR 97.25
- SLNO 64.59
About KMPR Kemper Corporation
Kemper Corp is a diversified insurance company that provides services in property and casualty insurance, along with life and health insurance. The company's property and casualty segment offers personal and commercial lines for home and automotive products. The company conducts its operations through two operating segments: Specialty Property & Casualty Insurance, and Life Insurance.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.